U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 28 results

Status:
US Approved Rx (2020)
First approved in 2013

Class (Stereo):
CHEMICAL (ACHIRAL)



Dimethyl fumarate (DMF) is the methyl ester of fumaric acid. DMF was initially recognized as a very effective hypoxic cell radiosensitizer. Later, DMF combined with three other fumaric acid esters (FAE) was licensed in Germany as oral therapy for pso...
Status:
US Approved Rx (2022)
First marketed in 1937

Class (Stereo):
CHEMICAL (ACHIRAL)



Niacin (also known as vitamin B3 and nicotinic acid) is bio converted to nicotinamide which is further converted to nicotinamide adenine dinucleotide (NAD+) and the hydride equivalent (NADH) which are coenzymes necessary for tissue metabolism, lipid ...
Status:
Investigational

Class (Stereo):
CHEMICAL (ABSOLUTE)



MK-1903 is a potent and selective hydroxycarboxylic acid receptor 2 (HCA2, GPR109A) full agonist. Exhibits no binding at the GRP109B receptor. This drug had been in phase II clinical trial for the treatment of atherosclerosis and Dyslipidemia. But th...
Status:
Investigational

Class (Stereo):
CHEMICAL (UNKNOWN)



Acifran (AY-25,712), an uncommercialized Ayerst compound exerting lipid-lowering activity in vivo, has been shown to also elicit similar effects as niacin in preliminary clinical testing and has been shown to bind to both high affinity (HM74A; GPR109...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

MK-0354 is a GPR109a (Niacin receptor 1) agonist, originated by Arena Pharmaceuticals. In phase II of clinical trials against dyslipidemia treatment with MK-0354 failed to produce changes in high-density lipoprotein cholesterol, low-density lipoprote...
Status:
Other

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

MK-6892 is niacin receptor 2 agonist, developed by Merkc. In preclinical experiments, it demonstrated reduction of free fatty acid levels by ~85%, with flushing side-effect evident only at the highest dose tested.
Status:
Possibly Marketed Outside US
First approved in 2014

Class (Stereo):
CHEMICAL (ACHIRAL)


Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ACHIRAL)



Acipimox (5-methylpyrazinecarboxylic acid 4-oxide) is a new lipolysis inhibitor that has a distant chemical relationship with nicotinic acid (NA). The anti-lipolytic action of acipimox is mediated through suppression of intracellular cyclic AMP leve...
Status:
US Approved Rx (2020)
First approved in 2013

Class (Stereo):
CHEMICAL (ACHIRAL)



Dimethyl fumarate (DMF) is the methyl ester of fumaric acid. DMF was initially recognized as a very effective hypoxic cell radiosensitizer. Later, DMF combined with three other fumaric acid esters (FAE) was licensed in Germany as oral therapy for pso...
Status:
US Approved Rx (2020)
First approved in 2013

Class (Stereo):
CHEMICAL (ACHIRAL)



Dimethyl fumarate (DMF) is the methyl ester of fumaric acid. DMF was initially recognized as a very effective hypoxic cell radiosensitizer. Later, DMF combined with three other fumaric acid esters (FAE) was licensed in Germany as oral therapy for pso...